Biosimilars: Global Markets

Report Scope

This report provides the current and future market potential of biosimilars, with market projections through 2029; and it includes a detailed analysis of the drivers, restraints and opportunities in the biosimilars market. The report also covers the competitive environment of the biosimilars industry and features a product analysis.

For this analysis, the market for biosimilars is segmented based on product type, therapeutic application and region. Based on product type, it is segmented into monoclonal antibodies, recombinant growth factors, recombinant hormones, fusion protein and others (such as LMWHs and interferons). Based on therapeutic application, the market is segmented into the following: cancer and related disorders, autoimmune and inflammatory diseases, diabetes, anemia, growth hormone deficiency and other diseases. Based on geographical region, the biosimilars market is segmented into the following: North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. For market estimate data, 2021 and 2022 serve as the historical years, 2023 as the base year, and 2029 as the forecast year.

The report provides company profiles of key players in the biosimilars market that feature detailed information about each organization’s business segments, financials, product portfolios and recent developments.

Report Includes

142 data tables and 74 additional tables

An analysis of the global market trends for biosimilars, with historic revenue data (sales figures) from 2021 and 2022, estimates for 2023, forecast for 2024, and projected CAGRs through 2029

Estimates of the market size and revenue growth prospects, along with a market share analysis by product type and sub-type, therapeutic application, and region

Facts and figures pertaining to the market dynamics, advances in existing biosimilars, regulations and the impact of macroeconomic factors

Review of the industry structure, emerging trends and developments, clinical trials and approvals, and new product

Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses

An analysis of key patent publications, grants and applications in biosimilars

Analysis of the competitive landscape featuring companies’ market shares, strategic alliances, M&A activity and a venture funding outlook

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies

Profiles of the market leaders, including Amgen Inc., Sandoz Group AG, Biocon Biologics Ltd., Pfizer Inc., and Teva Pharmaceutical Industries Ltd.

Companies Mentioned

ACCORD BIOPHARMA INC.
ALVOTECH
AMGEN INC.
AMNEAL PHARMACEUTICALS LLC.
BIOCON BIOLOGICS LTD.
BIOGEN
CELLTRION INC.
COHERUS BIOSCIENCES
FRESENIUS KABI AG
LILLY
PFIZER INC.
SAMSUNG BIOEPIS
SANDOZ GROUP AG
TEVA PHARMACEUTICAL INDUSTRIES LTD.
VIATRIS INC.